Caring for patients with rare diseases: Insights + recommendations from the 2024 Becker's-Alnylam survey
Rare diseases can be difficult to recognize, which often limits patients' access to necessary care and ultimately impacts patient outcomes. Ensuring patients are connected to the best possible care starts when health systems commit to reaching the right diagnosis as soon as possible.
Becker's Healthcare recently conducted a survey with Alnylam Pharmaceuticals to learn more about the treatment of rare diseases and the role of health systems' pharmacy operations.
Respondents said when it comes to identifying and treating rare disease patients, it is important for health systems to recognize there is more than one "right" approach to care. It is essential to look beyond the lens of the specialty pharmacy alone and consider more broadly what is best for patients, as well as the health system.
The results of the survey are summarized in a short but comprehensive whitepaper.
Key topics covered in this whitepaper:
Becker's Healthcare recently conducted a survey with Alnylam Pharmaceuticals to learn more about the treatment of rare diseases and the role of health systems' pharmacy operations.
Respondents said when it comes to identifying and treating rare disease patients, it is important for health systems to recognize there is more than one "right" approach to care. It is essential to look beyond the lens of the specialty pharmacy alone and consider more broadly what is best for patients, as well as the health system.
The results of the survey are summarized in a short but comprehensive whitepaper.
Key topics covered in this whitepaper:
- Increased education is key to improving rare disease diagnoses
- A flexible approach to administering rare disease therapies
- How the buy-and-bill model for rare disease treatments supports the Quintuple Aim
- Key requirements for optimized operational care pathways for patients with rare diseases
Please fill out the form to download the whitepaper.